Clearside Overview Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021. Quarterly Summary Show all Latest Quarterly Results Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update Clearside Biomedical Q3 2021 Financial Results and Corporate Update Call Form 10-Q View All News Releases Dec 21 2021 Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD Dec 13 2021 Clearside Biomedical Added to the Nasdaq Biotechnology Index Nov 16 2021 Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings View All Events Clearside Biomedical OASIS Trial Update Call Dec 21, 2021 at 8:30 AM EST Clearside Biomedical at the UBS Ophthalmology Day Dec 6, 2021 Clearside Biomedical at the BTIG Ophthalmology Day Nov 30, 2021 View All Stock Quote Change Volume 52 Week High 52 Week Low Jan 16, 2022 9:01 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed.